News | January 07, 2008

Brief Ischemia Episodes Create Cardioprotective Effect

January 7, 2008 - Ischemia experienced in brief episodes could protect the heart by preparing it for a heart attack, according to early findings from an animal study by researchers at the University of Cincinnati, which was published in the January issue of the American Journal of Physiology: Heart and Circulatory Physiology.

Rat hearts transfused with blood preconditioned by mini “stress tests” from reduced blood flow had significantly better reperfusion after heart attack-like ischemia than those that received a transfusion from donors that were not subjected to stress beforehand (P

Preconditioning activated a protective pathway called Janus kinase (JAK) to signal transducers and activators of transcription (STAT). The JAK-STAT pathway could offer a therapy against the damage of a heart attack.

A transfer of protection suggested that the effect was mediated by a soluble molecule released during brief periods of stress. Researchers indicated that this molecular mediator likely activates the JAK-STAT pathway.

Hearts that received effluent from preconditioned hearts but were treated with the JAK 2 inhibitor AG-490 recovered less than any other group.

Increased STAT-3 activation, reduced STAT-1 activation, and decreased expression of the pro-apoptotic protein Bax were associated with the protective effect.

Researchers do not yet know how long the cardioprotective effect lasts after a brief period of ischemia. However, "translating this phenomenon into a clinically useful tool may protect the myocardium from potential injury in a variety of settings," she said, "including acute myocardial infarction, cardiac revascularization surgery, supply/demand imbalance in congestive heart failure, and ischemia/reperfusion challenge following shock."

For more information: ajpheart.physiology.org


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now